Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer
- 1 September 2015
- journal article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 173 (3), 297-304
- https://doi.org/10.1530/eje-15-0304
Abstract
Background: Medullary thyroid cancer (MTC) is capable of secreting several proteins, such as calcitonin (Ct), carcinoembryonic antigen (CEA), chromogranin and others. Recently, we observed an aggressive MTC with high levels of serum carbohydrate antigen 19.9 (Ca 19.9) and a rapid evolution to death.Objective: The aim of this study was to evaluate whether high levels of serum Ca 19.9 could be a prognostic factor of death in patients with advanced MTC.Patients and methods: We measured Ca 19.9, CEA and Ct in 100 advanced structural recurrent/persistent MTC patients and in 100 cured or biochemically affected MTC patients. Clinical and pathological data were also collected.Results: Sixteen percent of the patients with advanced MTC had high levels of Ca 19.9. The group with abnormal Ca 19.9 levels had significantly higher levels of CEA and Ct compared with the group with normal values of Ca 19.9 (PP=0.04), independent from Ct doubling time.Conclusions: These results demonstrated that an elevated value of serum Ca 19.9 appears to be a predictive factor of poor prognosis in advanced MTC patients and identifies those cases with a higher risk of mortality in the short term.Keywords
This publication has 27 references indexed in Scilit:
- Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid CancerThyroid®, 2012
- RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)Clinical Endocrinology, 2011
- Prognostic Value of Histological and Immunohistochemical Characteristics for Predicting the Recurrence of Medullary Thyroid CarcinomaAnnals of Surgical Oncology, 2010
- Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta‐analysisClinical Endocrinology, 2010
- The prognostic value of tumor markers doubling time in medullary thyroid carcinoma - preliminary reportThyroid Research, 2010
- Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status reportPublished by Elsevier BV ,2009
- Medullary Thyroid Cancer: Management Guidelines of the American Thyroid AssociationThyroid®, 2009
- Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomasBritish Journal of Cancer, 2009
- Medullary Thyroid Carcinoma: Recent Advances and Management UpdateThyroid®, 1995
- Medullary Thyroid Carcinoma: Clinicopathologic Features and Long-Term Follow-Up of 65 Patients Treated During 1946 Through 1970Mayo Clinic Proceedings, 1992